ACOG Recommendations for Osteopenia Management
For women with osteopenia (T-score between -1.0 and -2.5), ACOG recommends using the FRAX tool to guide treatment decisions, with pharmacologic therapy indicated when the 10-year risk of major osteoporotic fracture reaches 20% or hip fracture risk reaches 3%, while all women should receive age-appropriate calcium and vitamin D supplementation plus lifestyle modifications regardless of treatment status 1.
Screening Recommendations
Screen all women age 65 and older with DEXA scanning 1. For postmenopausal women younger than 65, perform DEXA if they have:
- History of fragility fracture
- Body weight less than 127 lb (58 kg)
- Medications or diseases causing bone loss
- Parental history of hip fracture
Prevention Strategy for All Women
Calcium and Vitamin D Intake
Age-specific daily requirements 1:
- Ages 19-50: 1,000 mg calcium, 600 IU vitamin D
- Ages 51-70: 1,200 mg calcium, 600 IU vitamin D
- Ages 71+: 1,200 mg calcium, 800 IU vitamin D
Target serum vitamin D level: 20 ng/mL (50 nmol/L) for optimal bone health 1.
Lifestyle Modifications
Counsel all women on 1:
- Weight-bearing exercise (essential for bone health)
- Smoking cessation
- Reducing alcohol intake
These discussions should occur with females of all ages, not just those diagnosed with low bone density.
Treatment Algorithm for Osteopenia
Step 1: Calculate FRAX Score
For women with T-scores between -1.0 and -2.5, use FRAX to determine fracture risk 1.
Step 2: Apply Treatment Thresholds
Initiate pharmacologic treatment when 1:
- 10-year risk of major osteoporotic fracture ≥20%, OR
- 10-year risk of hip fracture ≥3%
Also consider treatment if the patient has had a low-trauma fracture, even if DEXA doesn't show osteoporosis 1.
Step 3: Select Pharmacologic Agent
First-line therapy: Bisphosphonates (based on patient preference) 1:
- Alendronate 5 mg daily or 35 mg weekly for prevention
- Risedronate 5 mg daily or 35 mg weekly for prevention
- Ibandronate 150 mg monthly or 2.5 mg daily for prevention
Alternative agents 1:
- Raloxifene 60 mg daily: Good option for younger postmenopausal women with osteopenia
- Denosumab: Reserved for women with high fracture risk
- Teriparatide: Only for severe osteoporosis or those with fractures (not typically for osteopenia)
- Calcitonin: Weakest evidence; use only if other treatments cannot be tolerated
Critical Pitfalls to Avoid
Don't treat all osteopenia automatically: The T-score alone doesn't determine treatment need—FRAX assessment is essential to avoid overtreatment 1.
Don't ignore low-trauma fractures: Even without osteoporosis on DEXA, a fragility fracture warrants treatment consideration 1.
Don't forget bisphosphonate contraindications: Esophageal abnormalities and inability to remain upright for 30 minutes are absolute contraindications to oral bisphosphonates 1.
Don't neglect lifestyle counseling: Nutrition and exercise discussions should occur regardless of whether pharmacotherapy is initiated 1.
Updated ACOG Guidelines (2021-2022)
The most recent ACOG Clinical Practice Guidelines 2, 3 provide comprehensive evidence-based recommendations for postmenopausal osteoporosis management, though the specific treatment thresholds and FRAX criteria from the 2013 bulletin 1 remain the operational standard for osteopenia management in clinical practice.